Your session is about to expire
← Back to Search
Radiation Therapy for Oropharyngeal Cancer
Study Summary
This trial is testing radiation and cisplatin with or without cetuximab to treat patients with HPV-positive oropharyngeal squamous cell carcinoma that has spread.
- Oropharyngeal Cancer
- KRAS Protein Variant
- Oropharyngeal Carcinoma
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Can people with the required qualifications sign up for this research project right now?
"That is correct. The information available on clinicaltrials.gov reveals that this study is still looking for 70 individuals to take part in the trial, which was first posted on 1/14/2020."
What are some common reasons why patients might undergo Radiation Therapy?
"malignant neoplasms located in the testes, head and neck squamous cell carcinoma, and certain epithelial ovarian tumours can all be treated with radiation."
What other scientific research studies have utilized Radiation Therapy?
"At the moment, 888 ongoing studies are researching Radiation Therapy with 321 trials in Phase 3. While a few of the studies for Radiation Therapy are situated in Shanghai, there are 49092 locations conducting research on this topic."
Does the FDA condone radiation as a treatment method?
"While there is some evidence to support the safety of Radiation Therapy, it received a score of 2 because Phase 2 trials have not yielded data in support of efficacy."
How many study participants are there in total?
"That is correct, the online information from clinicaltrials.gov does state that this particular trial is still recruiting patients. This study was first posted on January 14th 2020, with the most recent update taking place on October 13th 2022. Only 70 individuals are needed for participation at 1 location."
Share this study with friends
Copy Link
Messenger